| 000 | 01576 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250518081012.0 | ||
| 264 | 0 | _c20200918 | |
| 008 | 202009s 0 0 eng d | ||
| 022 | _a1879-114X | ||
| 024 | 7 |
_a10.1016/j.clinthera.2019.11.011 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDong, Shu-Jie | |
| 245 | 0 | 0 |
_aCost-effectiveness of Dabigatran Compared With Rivaroxaban for Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in China. _h[electronic resource] |
| 260 |
_bClinical therapeutics _c01 2020 |
||
| 300 |
_a144-156.e1 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAnticoagulants _xeconomics |
| 650 | 0 | 4 |
_aAtrial Fibrillation _xdrug therapy |
| 650 | 0 | 4 | _aChina |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 |
_aDabigatran _xeconomics |
| 650 | 0 | 4 |
_aEmbolism _xprevention & control |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMarkov Chains |
| 650 | 0 | 4 | _aModels, Economic |
| 650 | 0 | 4 | _aQuality-Adjusted Life Years |
| 650 | 0 | 4 |
_aRivaroxaban _xeconomics |
| 650 | 0 | 4 |
_aStroke _xprevention & control |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aWu, Bin | |
| 700 | 1 | _aZhai, Suo-Di | |
| 700 | 1 | _aZhang, Yan-Jun | |
| 700 | 1 | _aChu, Yun-Bo | |
| 700 | 1 | _aGupta, Parul | |
| 700 | 1 | _aLi, Ya-Huei | |
| 773 | 0 |
_tClinical therapeutics _gvol. 42 _gno. 1 _gp. 144-156.e1 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.clinthera.2019.11.011 _zAvailable from publisher's website |
| 999 |
_c30513070 _d30513070 |
||